CSL Ltd
XMUN:CSJ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
CSL Ltd
XMUN:CSJ
|
AU |
|
J
|
J.M. Smucker Co
F:JM2
|
US |
|
S
|
Saipem SpA
F:SPEA
|
IT |
Intrinsic Value
The intrinsic value of 
CSL Ltd (CSJ) under the Base Case is 69.36 EUR per share.
Compared with the current market price of 125.72 EUR, the stock appears
Overvalued by 45% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What CSL Does
CSL Ltd is a global biopharmaceutical company that makes medicines from human plasma and other biological materials. Its main products are treatments for immune disorders, bleeding disorders, and other serious conditions, plus vaccines for influenza and related infectious diseases. The company also sells iron and kidney-care therapies through its specialty medicines business.
- Headquarters
- Australia AU
- Employees
- 32 065
- IPO date
- Jun 8, 1994
CSL has no economic moat
Established rivals can supply competing plasma medicines, while generic alternatives limit protection for parts of CSL’s iron treatment business. CSL’s manufacturing expertise and product approvals create hurdles, but do not by themselves keep capable competitors from pursuing its customers and profits.
Read the full moat analysis
Earnings Waterfall
CSL Ltd
The intrinsic value for CSL Ltd (CSJ) under the Base Case is 69.36 EUR.
Compared with the current market price of 125.72 EUR, the stock appears Overvalued by 45% .
